Analysis of the survival of patients receiving systemic treatment for melanoma of the skin: a retrospective population study with patients treated in Poland in 2011–2015

Brzozowska, Melania; Wierzba, Waldemar; Śliwczyński, Andrzej; Majkut, Gabriela; Jacyna, Andrzej; Orlewska, Ewa; Potemski, Piotr; Marczak, Michał

doi:10.5114/ada.2019.83368

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, 43% ORR and 77% DCR were noted, and 19% ORR and 65% DCR were recorded in the 1995–2005 study. All the results obtained in our study are comparable with the treatment outcomes via new therapies in other centres in Poland [ 15 – 18 ] and other studies with real-world data [ 19 – 22 ].…”

Section: Resultssupporting

confidence: 89%

Real-world treatment practice in patients with advanced melanoma

Cybulska-Stopa¹,

Piejko²,

Pacholczak³

et al. 2020

View full text Add to dashboard Cite

Introduction The treatment outcomes of patients with advanced/metastatic melanoma were poor before the use of new therapeutic options. Material and methods A retrospective analysis was conducted among 287 patients with unresectable stage III and stage IV melanoma treated at the Maria Sklodowska-Curie National Research Institute of Oncology Cracow Branch, from 2013 to 2019. All enrolled patients were treated with immunotherapy (IT; consisting of pembrolizumab/nivolumab, or ipilimumab) or target therapy (TT; consisting of vemurafenib ±cobimetinib or dabrafenib ±trametinib) in at least one treatment line. Results mutation was detected in 152 (55%) patients. In general, the majority of patients (92%) were in very good or good condition (Eastern Cooperative Oncology Group [ECOG] 0 or 1). Brain metastasis was detected in 64 (22%) patients. Median OS and PFS in the experimental group from the beginning of the first-line treatment were 14.9 and 6.7 months, respectively. Across the study population, as a first-line treatment patients received IT, TT as well as CHT, and the median OS was 19.2, 12.6 and 15.9 months, respectively. Multivariate analysis confirmed that normal LDH levels, no brain metastases, ECOG 0, and objective response to the treatment were strong predictors of longer OS. For PFS, absence of brain metastases, ECOG 0, and treatment response were found to be predictive factors on multivariate analysis. Conclusions The administration of new therapies for the treatment of patients with advanced/disseminated melanoma significantly prolonged survival in this group of patients. Nevertheless, further studies should be conducted to assess the effectiveness of various sequences of treatment.

show abstract

Section: Resultssupporting

confidence: 89%

Real-world treatment practice in patients with advanced melanoma

Cybulska-Stopa¹,

Piejko²,

Pacholczak³

et al. 2020

View full text Add to dashboard Cite

show abstract

Wykorzystanie baz danych Narodowego Funduszu Zdrowia przy ocenie dowodów naukowych z praktyki klinicznej

Holko

Kawalec

2022

Zdrowie Publiczne I Zarządzanie

View full text Add to dashboard Cite

The use of the National Health Fund databases as a source of real-world evidence Patient medical records and administrative healthcare databases are possible sources of real-world evidence (RWE), i.e., evidence on the potential benefits and risks of a medical product. RWE can complement the evidence from randomized clinical trials. The wide range of information collected by the National Health Fund (NFZ) and the Ministry of Health in Poland ensures the versatility of the data that cover almost all patients treated in Poland. In addition to administrative data (without detailed information about patients and their disease), electronic medical records of some patient groups can be obtained from special programs (e.g., KOS-Zawał) or the System of Monitoring Drug Programs (SMPT). Low usage (only 37 studies) but high usability of NFZ databases as a source of RWE were identified. Joint analysis of data from administrative databases and SMPT can increase the credibility of the study, but limits the study to only patients treated within the Drug Programs.

show abstract

Analysis of the survival of patients receiving systemic treatment for melanoma of the skin: a retrospective population study with patients treated in Poland in 2011–2015

Cited by 2 publications

References 6 publications

Real-world treatment practice in patients with advanced melanoma

Real-world treatment practice in patients with advanced melanoma

Wykorzystanie baz danych Narodowego Funduszu Zdrowia przy ocenie dowodów naukowych z praktyki klinicznej

Contact Info

Product

Resources

About